LACTB2 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to impair the LACTB2 gene, a mitochondrial endoribonuclease critical for processing mitochondrial RNA. This product delivers a polyclonal mixture of edited NCI-H1975 cells, avoiding clonal selection and enabling investigation of population-level consequences of LACTB2 disruption. It serves as a robust platform for loss-of-function studies in a lung adenocarcinoma background, where mitochondrial RNA metabolism is intimately linked to tumor cell fitness and therapeutic response.
Originally isolated from a female patient with non-small cell lung cancer, the NCI-H1975 cell line harbors an oncogenic EGFR exon 19 deletion (E746-A750) and a TP53 missense mutation. These genetic hallmarks render the cells a widely utilized model for EGFR-targeted therapy research and p53-deficient tumor biology. The compromised DNA damage response and apoptosis regulation in this background create a permissive environment for examining mitochondrial perturbations that intersect with cell survival and drug sensitivity.
At the molecular level, LACTB2 functions within the mitochondrial matrix as an endoribonuclease that processes polycistronic mitochondrial transcripts, directly interacting with FASTKD2, PNPT1, and the MRPP1 complex to facilitate maturation of critical mRNAs such as MT-ND1 and MT-CO1. These transcripts encode essential subunits of Complex I and Complex IV of the oxidative phosphorylation system. LACTB2 activity is regulated by upstream mitochondrial biogenesis factors including PGC-1?? and NRF1, and is influenced by mitochondrial stress signals. Disruption of LACTB2 leads to impaired respiratory chain function, reduced ATP production, and destabilization of mitochondrial membrane integrity, promoting cytochrome c release and subsequent activation of caspase-9 and BAX-mediated apoptosis.
In the NCI-H1975 context, LACTB2 knockout is anticipated to impair mitochondrial gene expression, resulting in defective oxidative phosphorylation and metabolic reprogramming. This model enables dissection of the contributions of mitochondrial RNA processing to NSCLC pathobiology, including energetic stress, redox imbalance, and apoptosis evasion. Given the interplay between EGFR signaling and mitochondrial function, these cells are particularly valuable for exploring how LACTB2 loss influences EGFR-driven tumor maintenance and sensitivity to targeted agents.
Researchers can apply this knockout model to a diverse set of experimental workflows: RNA-seq analysis of the mitochondrial transcriptome to map processing defects; Seahorse metabolic flux assays to quantify oxygen consumption and glycolysis; Western blotting for OXPHOS subunits to assess respiratory chain stability; JC-1 flow cytometry to measure mitochondrial membrane potential; and Annexin V/PI staining to evaluate apoptotic priming. These approaches facilitate investigations into mitochondrial dysfunction, metabolic plasticity, and treatment resistance mechanisms in lung adenocarcinoma. For further technical specifications and ordering support, please contact Ascent Research.
